Investor Presentation

View our latest Investor Presentation to find the most recent investor-related information

Latest News

NeonMind Announces Decision to Seek A Buyer For Drug Development Program

November 8, 2022 3:45PM EDT Oakville, Ontario – November 8, 2022: NeonMind Biosciences Inc. (CSE: NEON) (FRA:6UF0) (“NeonMind” or the “Company”) announced the strategic decision

NeonMind Announces Organizational Changes

May 30, 2022 6:00pm EDT Oakville, Ontario – May 30, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF0) (“NeonMind” or the “Company”) announced today

NeonMind To Improve Patient Care and Data Management by Adopting Digital Platform for Ketamine Treatments in Preparation of Opening Its Inaugural Specialty Mental Health Clinic

April 21, 2021 8:00am EDT Engages Thrive Health, a Leading Digital Patient Care Platform to Streamline Care Programs and Data Collection OAKVILLE, ON / ACCESSWIRE

NeonMind Engages Leading Digital Platform for Medical Education and Adoption of Ketamine Treatments in Preparation of Opening its Inaugural Specialty Mental Health Clinic

April 11, 2021 8:00am EDT Initiates Medical Adoption Program with Impetus Digital, a Leading Healthcare Platform for Virtual Medical Education OAKVILLE, ON / ACCESSWIRE /

View All News

Email Alerts

Investor Presentation

View Presentation

Company Overview

NeonMind is an integrated psychedelic drug development and wellness company focused on therapeutic uses of psychedelics to address public health needs including obesity, weight management and mental health. NeonMind has two operating divisions, a pharmaceutical division engaged in drug development research for the potential therapeutic uses of psychedelic compounds, and a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.

View Management Team >

View Board of Directors >

Investor Contact Information

Company

NeonMind Biosciences Inc.
5 – 519 Dundas St. W.
Suite #511
Oakville, ON L6M 5K3
Canada

Investor Relations

T: +1 (705) 710-NEON /
+1 (705) 710-6366

Transfer Agent

Endeavor Trust Corporation
T: 604-559-8908
david@endeavortrust.com